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flrjectives.This study sought to assess the hemodymamicand
cardiac effectsof two dose levelsof mibefradil in patients with
varyingdegreesof ischemicleft ventriculardystlmction.
Background.Mibefradil is a new,selectiveT-typeand L-type
calciumchannelblockingagent,BecauseL-typechannelblockade
may depress myocardialperformance,an invasivehemodynamic
studywas performedto assess the safetyof this agent.
Methods,We performedan open label study, examiningthe
effectsof twointravenousdosesofmibefradil,selectedto produce
plasma levelscomparableto those measuredafter oral adminis-
tration of50mg (dose1:400rig/ml)or 100mg (dose2:800rig/ml)
of the drug,Variablesstudiedincludedthe indexesof leftventric-
ular function and neurohormonelevels.Patients were stratified
accordingto ejectionfraction(EF) (240%0,n = 26;<40%0,n = 24)




-12%, both p < 0.01)and also reducedend-systolicstress and
volume,thus improvingEF (52%to 581?0,p < 0.01),Heart rate
tended to decrease. In patients with depressed EF, heart rate
decreased significantlywith both doses. The effectsof dose 1
mimickedthose observedafter dose2 in patients with preserved
EF. Dose2 (plasmalevels1,052& 284rig/ml)still decreasedleft
ventricularsystolicwall stress and improvedEF (24.0%0to 28.5%,
p < 0.05) but also significantlydepressed the maximal first
derivativeof left ventricularpressure. Examinationof individual
pressure-volumeloopsin twopatientswithheart failureshoweda
clear rightward shift of the loop despite a decrease in systolic
pressure,suggestingnegativeinotropy.Neurohormonelevelswere
uuchangedat both dose levelsand in al[ subgroups.
Conclusions.Intravenous mibefradil was well tolerated and
producedan overallfavorablecardiovascularresponse.However,
highplasmaeancentrationsmightproducemyocardialdepression
in patients with heart failure, and caution should be exerted in
this setting,
(JAm CoilCardiol1996;28:972-9)
It is widelyrecognizedthat severalformulationsof calcium
channelblockingagentsare of no benefitand may even be
harmfulin acutecoronarysyndromes(1,2)and in congestive
heart failure(3,4).Controversyalsoexistsregardingthe long-
termuseof theseagentsin chronicstableanginaor hyperten-
sion(5–7).Beforeanyconclusionsare drawnas to the safety
andeffectivenessofcalciumchannelblockers,it isimportanto



















rivativemibefradil(Ro 40-5967)has been shown (8,9) to
selectivelyinhibit in vitro the T-type calciumchannelsat
concentrationsthat onlypartiallyblockedL-typecurrents.In
earlyclinicaltrialsandatplasmaconcentrationscomparableto
those used in the in vitro studies (9), mibefradilwas well





systemichemodynamicvariablesnot only in patients with
relativelynormal cardiac function,but also in those with











dP/dt = firstderivativeof leftventricularpressure
(dP/dt)iDP40= dP/dtmeasuredat a developedpressureof40mmHg
EF = ejectionfraction
LV = leftventricular
causethissubgroupis particularlysensitiveto the depressant
effectsof calciumentryblockade(3,4).
Methods
Protocol overview.The present studywas a two-center,
open label,ascending-dosetrial in whichthe safetyand acute
hemodynamicandcardiaceffectsofan intravenousinfusionof
mibefradilwere assessedin patients with coronaryartery




of mibefradil.Dose 1 (target concentration400 rig/ml)con-
sistedof a 15-minloadinginfusionat 1 mg/minfollowedby a
maintenanceinfusionat 0.42mg/minuntil the last measure-
ments were completed.Dose 2 (target concentration800
rig/ml)consistedof a 15-minloadinginfusionat 2.33mg/min
followedbya maintenanceinfusionat 0.75mg/min.The total
volumeof fluidinfusedrangedfrom 120ml after dose 1 to
220ml after dose 2. The hemodynamicand neurohormonal
measurementswereobtainedbeforeand30minafterthestart
of the loadinginfusion.
Patients. A total of 50 patientsscheduledfor diagnostic
cardiaccatheterizationand stratifiedaccordingto EF (=40%,
range4170to 7470,n = 26;<4070,range13Y0to 39T0,n = 24)
and the presence (n = 15, New York Heart Association
functionalclassII or III) or absence(n = 35,functionalclass
I) of clinicalsignsof congestiveheartfailurewereincludedin
the study.There were 45 male and 5 femalepatientswith a
mean age of 59 years (range 35 to 73), and there was no
significantd~erence in demographicvariablesbetweendose
groups.The patientsfulfillingthe selectioncriteria(seelater)
were assignedto treatment with mibefradilin a stepwise
fashionfor safetyreasons.Thus,patientswitha depressedEF
and heart failurereceiveddoses1 and 2 of mibefradilonly
whentheseregimenshad been shownto be safein the other
patients.
Eligibili@criteria. Tobe eligible,thepatientswererequired
to 1) be in sinusrhythm;2) havesignificantcoronaryarteV
disease (definedas stenosis=60% of at least one major
coronaryvesselor evidenceofa previousmyocardialinfarction
at least 1 monthbefore the study);and 3) meet the EF and
functionalclasscriteriaat each step. Patientswith unstable
angina,a recentmyocardialinfarction,atrioventricularblock
of anydegree,significantvalvularor nonischemicmyocardial
diseaseas wellwith any significantnoncardiacdiseasewere
excluded.All cardioactivedrugswere discontinuedat least 2
daysbefore the study,exceptfor angiotensin-convertingen-
zymeinhibitorsand short-actingnitrates,whichwere allowed
up to 12 and 2 h before the study,respectively.All patients
gavewritteninformedconsentto participate,and the study
protocolwasapprovedbythe ethicscommitteeat eachpartic-
ipatingcenter.
Data recording and analysis. Hemodynamic and angio-








computer system derived the correction factor for X-ray
magnificationand calculatedvolumesevery20msbyapplying





byaveragingdatafromthe start to the end ofejectionandthe
meandiastolicwallstressobtainedbyaveragingdatafromthe
start of diastolicfillingto end-diastole.Volumedata were
normalizedusing body surface area, and pressure–volume
loopswere plotted for each patient. Peak fillingrate was
calculatedusing a data smoothingprogram (14), and the
angiographicardiacindexwascalculatedas
AngiographicstrokevolumeindexXHeartrate.




at a developedpressureof 40 mm Hg [(dP/dt)/DP40(15)]—
and the timeconstantof isovolumetricpressuredecreasetau.
Systemicvascularresistancewascalculatedas
(Meanaorticpressure/Angiographiccardiacoutput)X80.
Plasma norepinephrine and plasma renin activity. Blood
samples for plasma norepinephrine levels, plasma renin activ-
ity and mibefradil concentrating were obtained at baseline,
before contrast material injection and after 30 min of infusion,
before the second set of angiographic measurements. Blood
samples were immediately chilled and centrifuged, and the
plasma sampleswere stored at –80”C until assayas described
previously (16). Plasma norepinephrine levels were deter-
mined by a radioenzymatic assay using the enzyme catechol-
o-methyl transferase (16). Plasma renin activitywas measured
by the method described by Scaly and Laragh (17). Plasma
mibefradil concentrations were determined by high perfor-
mance liquid chromatographywith fluorescence detection.
9’74 ROUSSEAUETAL.
CALCIUMENTRY BLOCKADEIN ISCHEMICLV DYSFUNCTION
JACC Vol. 28, No. 4
October 1996:972-9
Table1. Changesin HemodynamicVariablesin PatientsWithEjectionFraction>40%
Dose1 Dose2
Baseline ChangeFromBaseline Baseline ChangeFromBaseline
No.of No.of No.of No.of

































































































































































































“p<0.01.tp <0.05. CI = angiographiccardiacindex;circ= circumference;DAoP= diastolicaorticpressure;(dP/dt)/DP40= maximalfirstderivativeof left
ventricularpressure(dP/dt)measuredandnormafixedat a developedpressureof40mmHg;EF = ejectionfraction;ESWS= end-systolicwaflstress;HR = heart
rate;LVEDP= leftventricularend-diastolicpressure;LVEDVI= leftventricularend-diastolicvolumeindex;LVESVI= leftventricularend-systolicvolumeindex;
LVSP= leftventricularsystolicpressure;MAoP= meanaorticpressure;MDWS= meandiastolicwallstress;MSWS= meansystoficwallstress;Peak–dP/dt= peak
negativedP/dt;Peak+dP/dt= peakpositivedP/dt;PER= peakejectionrate;PFR= peakfillingrate;Pts= patients;SAOP= systolicaorticpressure;SVI= stroke
volumeindex;SVR = systemicvascularresistance;SWI = strokeworkindex;Tau = time constantof isovohrrnetncpressuredecrease;VCF = veloeityof
circumferentialfibershortening.
Statisticalanalysis. Becausethe primaryobjectiveof this
open study was safety, and because it did not includea
placebo-controlledgroup,eachgroupwasanalyzedseparately,
and the p valuespresented(two-tailed,basedon pairedttest
calculations)are consideredexplorative.To accountfor mul-
tiple comparisons,the two-tailedt test in each of the four
groupswasperformedonlyifa globaltestshoweda statistically
significantchangefrom baselinefor the selectedvariables
regardlessof a selectedgroup.Thisglobaltestwasperformed
usingan analysisofvariancewiththe changefrombaselineas
the dependentvariable,a classvariabledescribingthe four
groupsasthe independentvariableandexcludingthe intercept
variablefromthe model.In addition,the individualdatawere
reviewedto detect any outlier in whom the hemodynamic
responsecouldbe consideredunfavorable(i.e., decreasein
ejectionfractionand increasein end-systolicvolume,increase
in LV end-diastolicpressure,excessivedecreasein arterial
pressureor heart rate). The linearrelationbetweenEF and
end-systolicwall stress was derived using standard linear
regressiontechniques.
Results




summarizedin Tables1 and 2.
Effects of mibefradil in patients with preservedsystolic
fimction. In thisgroupof patients,the plasmalevelsreached
afterdoses1and2were446~ 66rig/ml(range323to 532,n =
13)and898t 196(range659to 1281,n = 13),respectively.No
clinicallysignificantchangesin hemodynamicor LV function
indexeswere evidentafter dose 1 in this subsetof patients.
However,dose2 induceda modestbut statisticallysignificant
vasodilation,as reflected by a 12!Z0decrease in systemic
vascularresistanceand by a 8.5-mmHg decreasein mean
aortic pressure (both p K 0.01).This decreasein systemic
impedanceresulted in a reduced LV afterload (–16% in
end-systolicwallstress,p < 0,05),andmeanLVEF improved
from52%to 58%(p < 0.01).Heart rate tendedto decrease,
.———
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Table2. Changesin HemodynamicVariablesin PatientsWithEjectionFraction<40%
Dose1 Dose2
Baseline ChangeFromBaseline Baseline ChangeFromBaseline
No.of No.of No.of No.of










































































































































































but cardiacindexandthe isovolumicindexesof relaxationand
inotropicstatewere unchanged.The changesin plasmanor-
epinephrineand plasmarenin activitywere also insignificant
(Table3).
Effects of mibefradil in patients with depressed systolic
ilmction. In thisstudygroup,the plasmalevelsreachedafter
doses1 and 2 were559f 238rig/ml(range250to 1165)and
1,052f 284rig/ml(range688to 1532),that is, -30% to 40%
higherthan predictedand higherthan in patientswith pre-
served LV function.In this subset,both doses induceda
significantreductionin heart rate, mean aorticpressureand




volumedata suggeststhat this decreasewas related to a
downwardshift in the pressure-volumeloop that occurred
duringdiastolein 70% of patientswithoutcongestiveheart
failure(CHF)andin 9 of 12patientswithCHFanda lowEF.
Theotherindexesofdiastolicfunction,suchaspeakfillingrate





Baseline Baseline Baseline Baseline
(meani SD) (mean* SD) (meant SD) (meant SD)
Norepinephrine(nghnl)
EF >40%(n = 13) 325.85? 91.68 45.62? 131.74 308.00t 92.38 91.92282.37
EF <40%(n = 12) 290.42t 151.26 43.33t 56.47 320.08* 164.52 78.83f 128.26
Plasmareninactivity
(rig/mlperh)
EF >40%(n= 13) 0.73* 0.54 0.02t 0.18 0.72t 0.51 -0.07 k 0.18
EF <40%(n = 12) 0.68t 0.65 -0.20 * 0.40 0.72f 0.71 -0.05 * 0.26
EF = ejectionfraction.
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geographicardiacindexwasunchangedat both doseslevels,
the indexesof inotropicstate and relaxationbecameslightly
butsignificantlydepressedaftertheadministrationofdose2of
mibefradil.However,all theseindexesare heart rate,preload
and afterloaddependent,and examinationof the LV and
aorticpressuretracingsrevealedthatinmanyofthesepatients,
neitherpeakpositivedP/dtnor (dP/dt)DP40remainedisovolu-
metricduringmibefradilinfusion(i.e.,dP/dthad to be mea-
suredat a meandevelopedpressureof68mmHg,whereasthe
meanarterialdiastolicpressurewas66mmHg),whichreduces
the valueof theseindexesto detecttrue changesin inotropic
state.
Therefore,to better characterizethe effectsof mibefradil
on cardiacinotropy,the relationbetweenEF and end-systolic
wall stress and the individualpressure-volumeloops was
examined.Figure 1 illustratesthe inverserelationsbetween
end-systolicwallstressand EF at baselineand duringmibe-
fradil infusion.There were no statisticallysignitlcantdiffer-
encesin the slopeof these tworelations.Furthermore,indi-
vidualdata pointsafter mibefradilwere stillwithinthe 9570
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performancebefore and after the short-term infusion of
mibefradil.
Analysisof the individualpressure-volumeloopsindicated
that in all but fourpatients,the decreasein systolicpressure
was accompaniedby a decreasein end-systolicvolume.Nev-
ertheless,afterdose1,and despitea decreasein peaksystolic
and end-systolicpressures,onepatientwithCHF (Patient12)
had an unchangedend-systolicvolume(Fig.2), whereasan-
otherpatientwitha lowEF but no CHF (not illustrated)had
an increasein end-systolicvolume.Furthermore,afterdose2,
end-systolicvolumewas clearly increased after mibefradil
despitea reductioninend-systolicpressurein twopatientswith
CHF (Patients36 and 39) (Fig.3). Suchan abruptrightward
shiftobservedin threepatientscanonlybe explainedin terms
of cardiacmechanicsby a negativeinotropiceffect.No such
shiftwasnotedafterdoses1or 2 in patientswitha presemed




Thepresentstudysoughtto assessthe safetyof short-term
administrationof the calciumchannel blocker mibefradil.
Calciumantagonistshavebeen implicatedin variousadverse
effects,includingaggravationofmyocardialischemiaandCHF





End-Systolic Wall Stress (kdyne/cm2)
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sion. Specizilattentionwas therefore directedtoward these
pharniacodynamiceffectsof mibefradil.
Effectson heart rate and neurohormones.The data indi-
cated that intravenousmibefradil,at dosesusedin the study,
primarilyacted as a mild arteriodilatorwith a relativelyflat
dose-responserelationandwastoleratedwellbytliepatients.
Of interestwasthe findingthat the drug,didnot tri~er reflex
tachycardia;rather, a slightbradycardiawas generallypro-




the T-typecalciumchannelsthat are predominantin pace-











































































EF <40%aridCHFbefore(opencircles)and after (soiidcircies)
administrationfrnibefradif(dose2).End-systolicvolumeincreased
substimtiailydespitereducedsystolicpressureintwopatients(Patients







VOLUME [ml/mz} musclecellswithpacemakerfunction(20).It is alsonotewor-
thy that no significantincreasesin plasma norepinephrine
levelsweredetectedat thegrouplevel,evenwhendatafromall
patientswere pooled.In fact, 27 patientshad increasesor
decreaseswellwithinthelimitsofthe analyticalmethodsused.
llventy-threepatients had an increase >15% of baseline
values.Thus,althoughsomedegreeof sympatheticactivation
mayhavebeenpresentin somepatients,the magnitudeof the
changesin plasmanorepinephrinelevelswasmuchlessthan
thatafterintravenousdihydropyridineadministration(21),and
a strong reflex sympatheticactivationis unlikelyto have
maskeda drug-inducedmyocardialdepression.Therewasalso
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the contrastmaterialon the juxtaglomerularapparatusmay
havecontributedto bluntthe response(12).
Effects on inotropic state. The direct effectsof calcium
channelblockerson LVinotropicstatearenotoriouslydifficult
to assessin the clinicalsetting.Usingthe classicalindexesof
inotropicstate and relaxation,no significantdirecteffectsof
mibefradilon myocardialperformancecouldbe detectedin
patientswitha preservedLVsystolicfunction.In patientswith
a lowEF, however,examinationof thepressure-volumeloops
yieldedsome evidenceof depressedmyocardialfunctionin
threepatients(onewithoutandtwowithCHF).In theabsence
of a placebogroup,it couldbe arguedthat suchchangescould
not be entirelydrugrelatedand mightalsoreflectthe impact
of the angiographicprocedures.Moreover,it is noteworthy
that despitesupratherapeuticoncentrations,no patientexpe-
rienced clinicallysignificanthemodynamicdeterioration,as
has been describedafter nifedipine(22).Nevertheless,that
thesethreepatientswereclusteredin the subgroupwitha low
EF, and the mostobviousdepressionof myocardialfunction
occurred after the highestdose in two of these patients,
suggeststhat thiswasa realpharmacologiceffect.Thishypoth-
esisis alsosupportedbythe findingthat the timeconstantof
isovolumicrelaxationwassignificantlyprolongedin this sub-
groupafterdose2 despitethe decreasein bloodpressureand
minimalchangesin heart rate. Patientswithheart failureare
known to have alterations in the excitation-contraction-
relaxationcoupling(23)andto be moresensitiveto L-channel
blockade(3,4,24).At the highestplasmalevelsobservedwith




recall that the plasma levelsmeasured in patientswith a
depressedEF were 30% to 40% higherthan predictedand
higherthan thosegenerallyrequiredto producea therapeutic
benefit (10).This pharmacokineticdifferencewas accompa-
nied by pharmacodynamiconsequences:The decreasesin
mean arterialpressurewere indeedof the same magnitude
afterdose1 in patientswitha lowEF (–9.0 mmHg)as those
afterdose2 (–8.5 mmHg)in patientswitha preservedEF. If
similarpharmacokineticdifferencesare present after oral
administration,thispresencesuggeststhat the doseof mibe-
fradilshouldbe reducedin patientswithpoorLVfunctionor
CHF,or both.




with evidenceof antianginal(10,25)and antihypertensive
properties,warrantsfurtherstudyof thiscompoundin a larger
population.Recentdata(26)obtainedwithamlodipinesuggest
that a subgroupof patientswithCHFmaybenefit,in termsof
survival,from calciumchannelblockertherapy.Whethera
similaror greater benefit can be providedby a relatively
specificT-type calciumchannelblocker is presentlybeing
investigatedin a large-scalemortalitytrial.Untilthe resultsof
this trial are available,cautionshouldstill be exertedwith
mibefradilin patientswith CHF in lightof the possibilityof
myocardialdepression.
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